Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Addition of Intravesical Recombinant Bacillus Calmette-Guérin to Perioperative Chemoimmunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/19.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.

Lancet (London, England)·2026

Same author

Individualized anticoagulation monitoring in critically ill patients: study protocol for a prospective observational comparison of Anti-Xa, viscoelastic testing, and thrombin generation.

Frontiers in medicine·2026

Same author

Physician-led telemedical care enhances blood pressure control in hypertension: a randomized-controlled pilot study (REMOTE-control-HTN).

European heart journal open·2026

Same author

Correction: Implementation of good clinical practice in clinical research in the context of limited resources settings: Lessons learnt from the freeBILy trial using an embedded mixed methods approach.

PLoS neglected tropical diseases·2026

Same author

Implementation of good clinical practice in clinical research in the context of limited resources settings: Lessons learnt from the freeBILy trial using an embedded mixed methods approach.

PLoS neglected tropical diseases·2026

Search research articles

Related Experiment Video

Updated: Aug 28, 2025

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

Decision-Making among Experts in Advanced Hodgkin Lymphoma.

Felicitas Hitz¹, Noémie Lang², Ulrich Mey³

¹Department of Medical Oncology/Hematology, Kantonsspital St.Gallen, St.Gallen, Switzerland.

|September 14, 2022

Summary

This summary is machine-generated.

Swiss experts reached consensus on first-line treatment for advanced Hodgkin lymphoma (aHL) using PET-guided therapy. However, treatment choices vary significantly for unfit patients, indicating a need for further clinical trials and guidelines.

Keywords:

Chemoimmunotherapy Decision-making Hodgkin lymphoma Immunotherapy Lymphoma Systemic therapy

More Related Videos

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

Related Experiment Videos

Last Updated: Aug 28, 2025

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

Area of Science:

Hematology
Oncology
Clinical Decision-Making

Background:

Advanced Hodgkin lymphoma (aHL) treatment involves numerous options, complicated by PET-guided decisions and novel therapies.
Complexity in treatment selection necessitates understanding expert decision-making processes.

Purpose of the Study:

To analyze decision-making practices for first-line treatment of aHL among Swiss experts.
To identify key criteria and consensus levels in aHL treatment selection.

Main Methods:

Thirteen Swiss experts described their institutional decision-making for aHL.
Decision trees were created to analyze expert algorithms and identify consensus and discrepancies.
Objective consensus methodology was applied.

Main Results:

Four primary decision criteria identified: age, fertility preservation, fitness, and interim PET scans.
Consensus achieved for treating young/fit and older/non-comorbid aHL patients.
Significant heterogeneity observed in treatment regimens for unfit patients and young females desiring fertility preservation.

Conclusions:

Four key criteria effectively represent expert approaches to first-line aHL treatment.
PET-guided curative treatment for aHL shows consensus among Swiss experts.
Treatment variability for unfit aHL patients underscores the need for clinical trials and specific recommendations.